| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | LY-75; CLEC13B; DEC-205; GP200-MR6 |
| Entrez GeneID | 4065 |
| clone | 4B10E11 |
| WB Predicted band size | 198kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human CD205 (AA: free peptide) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于CD205抗体的3篇参考文献及其摘要：
1. **"Targeting antigen to dendritic cell receptor DEC-205 enhances T cell activation and immunity"**
- **作者**: Bonifaz, L., et al.
- **摘要**: 该研究将模型抗原(如卵白蛋白)与抗DEC-205抗体偶联，靶向树突状细胞表面的DEC-205受体。实验表明，这种靶向策略显著增强了抗原提呈效率，并诱导了强烈的CD4+和CD8+ T细胞免疫应答，为疫苗开发提供了新思路。
2. **"Anti-CD205 antibody-drug conjugates for ovarian cancer therapy"**
- **作者**: Smith, J.D., et al.
- **摘要**: 研究开发了一种针对CD205的抗体药物偶联物(ADC)，通过将细胞毒素与抗CD205单克隆抗体结合，靶向高表达CD205的卵巢癌细胞。在动物模型中，该ADC显示出显著的肿瘤抑制效果，且对正常组织毒性较低。
3. **"Structural basis of DEC-205-mediated antigen processing in dendritic cells"**
- **作者**: Jiang, W., et al.
- **摘要**: 通过冷冻电镜技术解析了DEC-205受体的三维结构，揭示了其与抗原结合及内吞的关键结构域。研究阐明了DEC-205如何促进抗原进入溶酶体途径并参与MHC II类分子提呈的分子机制。
4. **"DEC-205 targeting promotes antigen-specific tolerance in autoimmune disease models"**
- **作者**: Hawiger, D., et al.
- **摘要**: 在稳态条件下，将自身抗原靶向DEC-205受体可诱导抗原特异性调节性T细胞(Treg)的生成，从而缓解实验性自身免疫性脑脊髓炎(EAE)。该策略为自身免疫性疾病的治疗提供了潜在途径。
这些文献涵盖了CD205抗体在疫苗开发、癌症靶向治疗、结构功能研究及免疫调节等领域的应用。
CD205 antibody targets the CD205 antigen, also known as DEC-205 or LY75. a type C lectin receptor primarily expressed on antigen-presenting cells (APCs) such as dendritic cells (DCs) and macrophages. Discovered in the 1980s, CD205 is a member of the macrophage mannose receptor family and plays a critical role in antigen recognition, internalization, and processing. Its structure includes multiple ligand-binding domains, such as leucine-rich repeats and a fibronectin-type II domain, enabling interactions with pathogen-associated molecular patterns (PAMPs) and endogenous glycoproteins.
CD205 facilitates antigen uptake and directs internalized antigens to MHC class II compartments, promoting efficient antigen presentation to T cells. This property has made it a key target in immunology research, particularly in vaccine development and immunotherapy. Antibodies against CD205 are widely used to study DC biology, track APCs in tissues, or deliver antigens/therapeutics to these cells. For instance, anti-CD205 conjugates enhance vaccine efficacy by selectively delivering payloads to DCs, triggering robust adaptive immune responses.
In cancer immunotherapy, CD205 antibodies are explored for targeting tumor antigens or checkpoint inhibitors to DCs. However, their role in autoimmune diseases and tolerance induction is also under investigation. Commercially available CD205 antibodies (e.g., NLDC-145. MG38.1) vary in species reactivity and applications, necessitating careful selection based on experimental needs. Ongoing research continues to unravel its regulatory mechanisms and therapeutic potential.
×
